{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:51Z","timestamp":1789194471303,"version":"build-2803163510"},"reference-count":54,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.2967\/jnumed.125.271268","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:50:14Z","timestamp":1767891014000},"page":"352-359","source":"Crossref","is-referenced-by-count":2,"title":["Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach"],"prefix":"10.2967","volume":"67","author":[{"given":"May","family":"Abdel-Wahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giammarile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026030205300679000_67.3.352.1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3892\/mco.2014.449","article-title":"Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis","volume":"3","author":"Furubayashi","year":"2015","journal-title":"Mol Clin Oncol."},{"key":"2026030205300679000_67.3.352.2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-012-0190-8"},{"key":"2026030205300679000_67.3.352.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026030205300679000_67.3.352.4","doi-asserted-by":"crossref","first-page":"20170948","DOI":"10.1259\/bjr.20170948","article-title":"18F-NaF\/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome","volume":"91","author":"Jadvar","year":"2018","journal-title":"Br J Radiol."},{"key":"2026030205300679000_67.3.352.5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol."},{"key":"2026030205300679000_67.3.352.6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11912-021-01042-w","article-title":"Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer","volume":"23","author":"Sun","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"2026030205300679000_67.3.352.7","doi-asserted-by":"crossref","first-page":"20150042","DOI":"10.1259\/bjr.20150042","article-title":"Improving external beam radiotherapy by combination with internal irradiation","volume":"88","author":"Dietrich","year":"2015","journal-title":"Br J Radiol."},{"key":"2026030205300679000_67.3.352.8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jrr\/rraf002","article-title":"Investigation of the safety of radium-223 chloride in combination with external beam radiotherapy for bone metastases of prostate cancer","volume":"66","author":"Makino","year":"2025","journal-title":"J Radiat Res."},{"key":"2026030205300679000_67.3.352.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J Icru."},{"key":"2026030205300679000_67.3.352.10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2478\/raon-2019-0058","article-title":"Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment","volume":"54","author":"Frantellizzi","year":"2019","journal-title":"Radiol Oncol."},{"key":"2026030205300679000_67.3.352.11","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer: from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics."},{"key":"2026030205300679000_67.3.352.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"2026030205300679000_67.3.352.13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.brachy.2022.04.006","article-title":"Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost","volume":"21","author":"Kollmeier","year":"2022","journal-title":"Brachytherapy."},{"key":"2026030205300679000_67.3.352.14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.rpor.2018.05.007","article-title":"Radiobiological considerations in combining doses from external beam radiotherapy and brachytherapy for cervical cancer","volume":"23","author":"Tornero-L\u00f3pez","year":"2018","journal-title":"Rep Pract Oncol Radiother."},{"key":"2026030205300679000_67.3.352.15","first-page":"100885","article-title":"Radiobiology and modelling in brachytherapy: a review inspired by the ESTRO brachytherapy pre-meeting course","volume":"50","author":"Stewart","year":"2025","journal-title":"Clin Transl Radiat Oncol."},{"key":"2026030205300679000_67.3.352.16","doi-asserted-by":"crossref","first-page":"e35612","DOI":"10.1002\/cncr.35612","article-title":"Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: consensus recommendations from the US Prostate Cancer Conference 2024","volume":"131","author":"Bryce","year":"2025","journal-title":"Cancer."},{"key":"2026030205300679000_67.3.352.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265025"},{"key":"2026030205300679000_67.3.352.18","first-page":"41","article-title":"Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET\/CT and multi-parametric MRI","volume":"32","author":"Liu","year":"2022","journal-title":"Clin Transl Radiat Oncol."},{"key":"2026030205300679000_67.3.352.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-022-00518-7","article-title":"Variability of radiotherapy volume delineation: PSMA PET\/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Imaging."},{"key":"2026030205300679000_67.3.352.20","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00259-017-3744-y","article-title":"The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer","volume":"44","author":"Murray","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030205300679000_67.3.352.21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/pharmaceutics15061733","article-title":"Clinical advances and perspectives in targeted radionuclide therapy","volume":"15","author":"Lepareur","year":"2023","journal-title":"Pharmaceutics."},{"key":"2026030205300679000_67.3.352.22","doi-asserted-by":"crossref","first-page":"100010","DOI":"10.1016\/j.eanmi.2025.100010","article-title":"Defining synergy of integrating radiotherapy and radioligand therapy: insights from ESTRO 2025","volume":"1","author":"Sollini","year":"2025","journal-title":"EANM Inn."},{"key":"2026030205300679000_67.3.352.23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41181-023-00230-2","article-title":"Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework","volume":"9","author":"Korde","year":"2024","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026030205300679000_67.3.352.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00030-5"},{"key":"2026030205300679000_67.3.352.25","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030205300679000_67.3.352.26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ijrobp.2020.12.002","article-title":"Overcoming barriers to radiopharmaceutical therapy (RPT): an overview from the NRG-NCI working group on dosimetry of radiopharmaceutical therapy","volume":"109","author":"Divgi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026030205300679000_67.3.352.27","doi-asserted-by":"crossref","first-page":"fmed-09-1070392","DOI":"10.3389\/fmed.2022.1070392","article-title":"Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"O\u2019Sullivan","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2026030205300679000_67.3.352.28","first-page":"665","article-title":"Guidance on prevention of unintended and accidental radiation exposures in nuclear medicine","volume":"39","author":"Martin","year":"2019","journal-title":"J Radiol Prot."},{"key":"2026030205300679000_67.3.352.29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00259-017-3921-z","article-title":"Correction to: dosimetry in clinical radionuclide therapy: the devil is in the detail","volume":"45","author":"Giammarile","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030205300679000_67.3.352.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0338-5"},{"key":"2026030205300679000_67.3.352.31","doi-asserted-by":"crossref","first-page":"12891","DOI":"10.3390\/ijms252312891","article-title":"Replacing 2 Gy per fraction equivalent dose with fractionation-specific biological equivalent dose for normal tissues","volume":"25","author":"Luo","year":"2024","journal-title":"Int J Mol Sci."},{"key":"2026030205300679000_67.3.352.32","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ijrobp.2024.02.005","article-title":"Voxel-level dosimetry for combined iodine 131 radiopharmaceutical therapy and external beam radiation therapy treatment paradigms for head and neck cancer","volume":"119","author":"Adam","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026030205300679000_67.3.352.33","doi-asserted-by":"crossref","first-page":"1530580","DOI":"10.3389\/fonc.2025.1530580","article-title":"Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy","volume":"15","author":"Poon","year":"2025","journal-title":"Front Oncol."},{"key":"2026030205300679000_67.3.352.34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","article-title":"Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naive patients, phase I study (PROQURE-I trial)","volume":"23","author":"Van der Sar","year":"2023","journal-title":"BMC Cancer."},{"key":"2026030205300679000_67.3.352.35","first-page":"1437","article-title":"Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report","volume":"33","author":"Mertens","year":"1992","journal-title":"J Nucl Med."},{"key":"2026030205300679000_67.3.352.36","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90309-J"},{"key":"2026030205300679000_67.3.352.37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000475428","article-title":"A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone","volume":"26(suppl 1)","author":"McEwan","year":"1994","journal-title":"Eur Urol."},{"key":"2026030205300679000_67.3.352.38","doi-asserted-by":"publisher","DOI":"10.3310\/hta20220"},{"key":"2026030205300679000_67.3.352.39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx044"},{"key":"2026030205300679000_67.3.352.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026030205300679000_67.3.352.41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026030205300679000_67.3.352.42","doi-asserted-by":"crossref","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"EClinicalMedicine."},{"key":"2026030205300679000_67.3.352.43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol."},{"key":"2026030205300679000_67.3.352.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"2026030205300679000_67.3.352.45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.15988","article-title":"LUNAR: a randomized phase 2 study of 177lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)","volume":"132","author":"Ma","year":"2023","journal-title":"BJU Int."},{"key":"2026030205300679000_67.3.352.46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026030205300679000_67.3.352.47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int."},{"key":"2026030205300679000_67.3.352.48","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026030205300679000_67.3.352.49","doi-asserted-by":"crossref","unstructured":"Sartor O Kiess A Feng F . PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC) [abstract]. J Clin Oncol. 2025;43(suppl 16):TPS5127.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127"},{"key":"2026030205300679000_67.3.352.50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","article-title":"Update to a randomized controlled trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial","volume":"22","author":"Priv\u00e9","year":"2021","journal-title":"Trials."},{"key":"2026030205300679000_67.3.352.51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MOU.0000000000001323","article-title":"VISION, TheraP, LuTectomy and beyond: is there a role for lutetium therapy in biochemical recurrence?","volume":"35","author":"Hennes","year":"2025","journal-title":"Curr Opin Urol."},{"key":"2026030205300679000_67.3.352.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026030205300679000_67.3.352.53","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S1470-2045(25)00559-5","article-title":"Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial","volume":"26","author":"Kostos","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026030205300679000_67.3.352.54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:30:20Z","timestamp":1772458220000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.2967\/jnumed.125.271268"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271268","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}